Arcutis Biotherapeutics, Inc. (ARQT) News
Follow Arcutis Biotherapeutics, Inc. (ARQT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
WESTLAKE VILLAGE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
NEWS | Sep 29, 2026, 01:18 PM UTC
L
NexPoint Residential, Amerisafe, Cogent exit S&P SmallCap 600
NexPoint Residential Trust, Amerisafe, and Cogent Communications will leave the S&P SmallCap 600.
EQUITY | Sep 04, 2026, 09:43 PM UTC
M
S&P SmallCap 600 to drop Shenandoah, Verra, Matthews, Franklin BSP
Shenandoah Telecommunications, Verra Mobility, Matthews International and Franklin BSP Realty to leave the S&P SmallCap 600.
EQUITY | Sep 04, 2026, 09:41 PM UTC
L
AXTI, ARQT, ATRC and EAT to join S&P SmallCap 600
AXTI, ARQT, ATRC and EAT are set to join the S&P SmallCap 600 index.
EQUITY | Sep 04, 2026, 09:38 PM UTC
L
Arcutis grants 57,000 RSUs under Nasdaq Rule 5635(c)(4)
Arcutis Biotherapeutics announced the grant of an aggregate 57,000 restricted stock units (RSUs) under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
ARQT reports inducement grants under Nasdaq Rule 5635(c)(4)
Arcutis Biotherapeutics (ARQT) reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:00 PM UTC
L
ARQT - Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ARQT - Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 02, 2026, 08:00 PM UTC
L
Arcutis Biotherapeutics director sells shares worth $956K+
Director of Arcutis Biotherapeutics sold shares worth over $956K, according to TradingView News.
EQUITY | Aug 28, 2026, 09:50 PM UTC
L
Arcutis Canada's Zoryve cream wins Health Canada approval for children 2 to 5
Arcutis Canada says Zoryve cream 0.05% receives Health Canada approval for children aged 2 to 5 years with mild to moderate atopic dermatitis.
REGULATION | Aug 20, 2026, 05:26 PM UTC
L
ARQT - Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
ARQT - Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 05, 2026, 08:00 PM UTC
L
ARQT Arcutis expands Board of Directors with appointment of Chris peetz
ARQT Arcutis expands Board of Directors with appointment of Chris peetz
EQUITY | Jul 16, 2026, 01:02 PM UTC
L
Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema
() -- Arcutis Biotherapeutics (ARQT) said Wednesday that the FDA accepted its application to expand ZORYVE cream 0.05% for infants with mild-to-moderate atopic dermatitis and has set a PDUFA action date of Feb. 23. The f
REGULATION | Jul 08, 2026, 12:59 PM UTC
L
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental new drug application, or sNDA, for Zoryve cream 0.05% to expand the indication for the topical treatment of mild to moderate atopic dermatitis
EQUITY | Jul 08, 2026, 12:13 PM UTC
L
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
2026-07-03 08:57:20 ET Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and
EQUITY | Jul 03, 2026, 01:02 PM UTC
M
Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the bod
REGULATION | Jun 30, 2026, 07:56 AM UTC